News

Stay up to date on the latest news and tweets of the Pereira Lab!

Spin-off From Pereira Lab Raises 6M Euros to Advance In vivo DC Reprogramming

Asgard Therapeutics AB, a private biotech company spin off from the Pereira Lab, announces the completion of a EUR 6 million seed financing round. The financing was co-led by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.

Fábio Rosa Defended His PhD Thesis

On June 10th 2021, Fábio Rosa defended his thesis “Generating Dendritic Cells by Direct Cell Reprogramming. Merging cellular reprogramming with immunology towards the development of novel cancer immunotherapies.” with Prof. Thomas Graf from the Center for Genomic Regulation (Spain) as opponent.

Filipe Pereira Is The New Editor-in-Chief of Cellular Reprogramming

Following on the legacy of Professor Sir Ian Wilmut, Filipe Pereira becomes the new Editor-in-Chief of the Cellular Reprogramming Journal.

Latest Tweets

I am happy to announce we were awarded with NBIS/@SciLifeLab Bioinformatics Long-term Support (a.k.a. WABI) - an excellent Swedish program that instead of $$$, grants >200 hours of bioinformatic help! Looking forward to develop data-centric projects together! @Lund_Stem @LuWcmm

Incredibly excited to share Asgard Therapeutics's http://asgardthx.com seed round news!

6 M Euros from the world-leading @NovoHoldings, @BoehringerIngelheim Venture Fund and @Industrifonden to advance our Trojan horse armed with immune #reprogramming skills!

#immunotherapy

Load More...